Articles & Video
Novel technologies and approaches for optimizing antibody discovery - WHITEPAPER
This whitepaper examines some of the latest advancements in methods and technologies innovating the discovery of antibodies.
47% of antibody engineering professionals using next generation sequencing
We take a deep dive into the data around the implementation of technology in antibody engineering and therapeutics from our recent industry survey.
REPORT: Emerging Technologies and Novel Approaches in Antibody Engineering and Therapeutics
Download the data report exploring Emerging Technologies and Novel Approaches in Antibody Engineering and Therapeutics.
Bispecific antibody ongoing clinical trials
We look at the bispecific antibody clinical trials - both oncological and non-oncological - currently running.
What is an antibody?
Learn what antibodies are, as well as types of antibodies, antibody anatomy, and the difference between an antigen and antibody.
Emerging technologies in antibody engineering and therapeutics
This whitepaper looks at the latest emerging technologies and novel approaches to antibody engineering and therapeutics.
The emergence and benefits of bispecific antibodies
We deep dive into the benefits of bispecific antibodies over mAbs and look at T Cell Engagers, dual-affinity retargeting and killer cell engagers.
Designing novel protein therapeutics and identifying appropriate targets - WHITEPAPER
This whitepaper explores designing novel protein therapeutics and identifying appropriate targets - download it here.
Bispecific antibody engineering and therapeutics - WHITEPAPER
The whitepaper explores the latest developments, technologies and challenges in bispecific antibody engineering and therapeutics. Download it here.
INDUSTRY VOICES: Next gen biologics benefits, investment and challenges
Four industry experts discuss the benefits, investment and challenges around next generation biologics.
42% of N American antibody therapeutic companies manufacture externally
We recently conducted a survey of antibody therapeutics professionals, revealing an overview of the state of the industry in 2019. Here we take a deep dive into the results around antibody manufacturing and drug delivery.
If you could ask your antibody therapeutics regulatory authority one question, what would it be?
Our recent survey revealed what antibody therapeutics professionals really think of the regulatory agencies governing the industry.
Novel Immuno-Oncology and Immunotherapeutic Approaches - WHITEPAPER
This whitepaper looks at the latest advances, technologies and challenges in immuno-oncology drug development. Download it here.
Dr John McCafferty on how his antibody phage display work contributed to a Nobel Prize
Dr John McCafferty, founder of IONTAS, explains how his pivotal work on antibody phage display helped contribute to the Nobel Prize in Chemistry 2018 in this exclusive interview.
The Future of Monoclonal Antibodies - WHITEPAPER
This whitepaper explores the current state and future of the monoclonal antibodies market and FDA approved monoclonal antibodies.
State of the Antibody Therapeutics Industry Report 2018
This exclusive report reveals unique insights into the state of the antibody engineering and therapeutics industry in 2018 based on the survey responses of 174 professionals.
The competitive advantages of next gen protein therapeutics over traditional mAbs
We explore the competitive advantages that next gen protein therapeutics offer over traditional monoclonal antibodies.
Using next gen protein therapeutics over traditional mAbs - WHITEPAPER
This exclusive whitepaper explores how different approaches to next gen proteins offer competitive advantages over traditional mAbs.
The advantages of therapeutic antibodies over chemotherapeutics
Sahar Mohseni NodehiPhD, Scientist, The Antibody Society, speaks on the advantages of therapeutic antibodies.